Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy

• Published in: Annals of surgical oncology 2024-12, Vol.31 (13), p.8813-8820
• Main Authors: Limberg, Jessica N., Jones, Tyler, Thomas, Samantha M., Ntowe, Koumani W., Dalton, Juliet C., van den Bruele, Astrid Botty, Wang, Ton, Plichta, Jennifer K., Rosenberger, Laura H., DiNome, Maggie L., Chiba, Akiko
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Axilla; Biopsy; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Breast Oncology; Chemotherapy; Chemotherapy, Adjuvant; Community centers; ErbB-2 protein; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph nodes; Lymph Nodes - pathology; Lymph Nodes - surgery; Lymphatic Metastasis; Lymphatic system; Medicine; Medicine & Public Health; Middle Aged; Neoadjuvant Therapy - mortality; Neoplasm, Residual; Oncology; Prognosis; Regression analysis; Retrospective Studies; Sentinel Lymph Node Biopsy; Surgery; Surgical Oncology; Survival Rate
• ISSN: 1068-9265; 1534-4681; 1534-4681
• DOI: 10.1245/s10434-024-16143-6

Background Axillary management after neoadjuvant chemotherapy (NAC) is evolving but axillary lymph node dissection (ALND) remains the standard of care for patients with residual nodal disease. The results of the Alliance A011202 trial evaluating the oncologic safety of ALND omission in this cohort are pending but we hypothesize that ALND omission is already increasing. Methods The National Cancer Database was queried to identify patients diagnosed with cT1-3N1M0 breast cancer who underwent NAC and had residual nodal disease (ypN1mi-2) from 2012 to 2021. Temporal trends in omission of completion ALND were assessed annually. Multivariable logistic and Cox regression models were used to identify factors associated with ALND omission and overall survival (OS), respectively. Results A total of 6101 patients were included; the majority presented with cT2 disease (57%), with 69% HER2+, 23% triple-negative, and 8% hormone receptor-positive/HER2−. Overall, 34% underwent sentinel lymph node biopsy (SLNB) alone. Rates of ALND were the lowest in the last 4 years of observation. After adjustment, treatment at community centers (vs. academic) and lower pathologic nodal burden were associated with omission of ALND. ALND omission was associated with a higher unadjusted OS (5-year OS: 86% SLNB alone vs. 84% ALND; log-rank p  = 0.03), however this association was not maintained after adjustment. Conclusions Despite the impending release of the Alliance A011202 results, omission of ALND in patients with residual nodal disease after NAC is increasing. This practice appears more prominent in community centers and in patients with a lower burden of residual nodal disease. No association with OS was noted.